Takarazuka, Japan

Atuyuki Kojima

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharmaceuticals Company Limited. Active years: 1988.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Atuyuki Kojima: Innovator in Antipsychotic Agents

Introduction

Atuyuki Kojima is a notable inventor based in Takarazuka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antipsychotic agents. His innovative work has led to the creation of a unique compound that holds promise for mental health treatments.

Latest Patents

Atuyuki Kojima holds a patent for "Imide derivatives and compositions for use as antipsychotic agents." This patent describes a compound of the formula: ##STR1## wherein A is a carbonyl group or a sulfonyl group. This invention represents a significant advancement in the search for effective treatments for psychiatric disorders.

Career Highlights

Kojima is associated with Sumitomo Pharmaceuticals Company Limited, where he has been instrumental in research and development. His work focuses on creating innovative solutions that address complex health issues. With a total of 1 patent, he has established himself as a valuable contributor to the pharmaceutical industry.

Collaborations

Throughout his career, Atuyuki Kojima has collaborated with esteemed colleagues, including Fujio Antoku and Kikuo Ishizumi. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Atuyuki Kojima's contributions to the field of antipsychotic agents highlight his dedication to improving mental health treatments. His innovative spirit and collaborative efforts continue to inspire advancements in pharmaceuticals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…